Cardiome Pharma Co. (TSE:COM) (NASDAQ:CRME) – Stock analysts at B. Riley issued their FY2018 EPS estimates for Cardiome Pharma in a research note issued to investors on Tuesday, December 4th. B. Riley analyst D. Buck anticipates that the biopharmaceutical company will post earnings of ($1.35) per share for the year. B. Riley has a “Buy” rating on the stock. B. Riley also issued estimates for Cardiome Pharma’s FY2019 earnings at ($0.87) EPS, FY2020 earnings at ($0.46) EPS, FY2021 earnings at $0.07 EPS and FY2022 earnings at $0.73 EPS.
Cardiome Pharma has a 1-year low of C$1.64 and a 1-year high of C$6.06.
Cardiome Pharma Company Profile
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients.
Featured Article: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.